文献速递主动脉疾病

现货多分支内移植物治疗胸腹主动脉瘤与近肾腹主动脉瘤:G-Branch内移植物的前瞻性单中心研究

Off the Shelf Multibranched Endograft for Thoraco-Abdominal and Pararenal Abdominal Aortic Aneurysms: a Prospective, Single Centre Study of the G-Branch Endograft.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2023-11-04

该前瞻性单中心研究纳入15例胸腹主动脉瘤或近肾腹主动脉瘤患者,于2019年10月至2021年3月接受G-Branch内移植物治疗,技术成功率为100%。中位随访31.4个月,30天死亡率为0、并发症率为7%,1年死亡率为7%、并发症率为13%,1年主要分支通畅率为100%,结论认为该移植物取得高技术成功率且早中期结果良好,尚需大型多中心研究。

要点

  • 15例胸腹主动脉瘤或近肾腹主动脉瘤患者接受G-Branch内移植物治疗,技术成功率为100%。
  • 30天死亡率为0、并发症率为7%,1年死亡率为7%、并发症率为13%。
  • 1年主要分支通畅率为100%,无动脉瘤扩张、再干预或入路相关并发症。

核心结论

  • G-Branch内移植物治疗胸腹主动脉瘤和近肾腹主动脉瘤取得高技术成功率且早中期结果良好,尚需大型多中心研究。

研究设计与样本

  • 前瞻性单中心研究,纳入2019年10月至2021年3月接受G-Branch内移植物(Lifetech Scientific,深圳,中国)治疗的15例胸腹主动脉瘤或近肾腹主动脉瘤患者(平均年龄63.4±10.7岁,13例男性)。
  • G-Branch内移植物采用混合多分支设计,两个内分支和两个外分支分别用于重建内脏动脉和双侧肾动脉。
  • 随访安排在出院前及术后30天、6个月和12个月,12个月后每年进行电话访谈,采用Kaplan-Meier法估算累积死亡率和并发症率。

主要发现

  • 全部15例患者技术成功,其中9例(60%)为胸腹主动脉瘤、6例(40%)为近肾腹主动脉瘤,平均最大动脉瘤直径为73.7±15.8 mm。
  • 中位随访31.4个月(范围10.1-44.0个月);30天无死亡,并发症率为7%(1例第4天短暂性脊髓缺血)。
  • 1年死亡率为7%(1例死于术后10个月卒中),并发症率为13%(另1例术后6个月肾功能下降)。
  • 无动脉瘤扩张、再干预或入路相关并发症,2例(13%)持续II型内漏;全部13例接受CT检查的患者中,四支肾内脏动脉的1年主要分支通畅率为100%。
  • 1例患者术后29个月死于肝细胞癌,估算三年死亡率为13%。

局限性

  • 原文结论提出尚需大型多中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate outcomes of a novel, off the shelf multibranched endovascular stent graft for the treatment of thoraco-abdominal aortic aneurysm (TAAA) and pararenal abdominal aortic aneurysm (PAAA). METHODS: A prospective, single centre study including 15 patients (mean age, 63.4 ± 10.7 years; 13 male) with TAAA or PAAA treated from October 2019 to March 2021 with a G-Branch endograft (Lifetech Scientific, Shenzhen, China) featuring a mixed multibranch design with two inner and two outer branches for reconstruction of the visceral and bilateral renal arteries, respectively. Follow up assessments were scheduled before discharge and at 30 days, six and 12 months after the index procedure. Annual telephone interviews were performed beyond the initial 12 months. The Kaplan-Meier method was used to estimate cumulative mortality and morbidity rates after endovascular repair. RESULTS: Technical success was achieved in all 15 patients. Nine patients (60%) had TAAA and six (40%) had PAAA (mean maximum aneurysm diameter, 73.7 ± 15.8 mm). The median follow up was 31.4 months (range, 10.1 - 44.0 months). At 30 days, there was no death and 7% morbidity (one case of temporary spinal cord ischaemia on Day 4). At one year, the mortality rate was 7% (one death from stroke at 10 months) and morbidity was 13% (one other case of renal function decline at six months). There were no aneurysm dilatations, re-interventions, or access related complications, and two (13%) persistent type II endoleaks. The one year primary branch patency rate was 100% for the four renovisceral arteries in all 13 patients who underwent computed tomography examinations. One patient died of hepatocellular carcinoma 29 months post-operatively, resulting in an estimated three year mortality rate of 13%. CONCLUSION: The G-Branch endograft yielded high technical success with good early and midterm outcomes for the treatment of TAAA and PAAA. A large multicentre study is warranted.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Zhang HP, Ge YY, Wang JB, et al. Off the Shelf Multibranched Endograft for Thoraco-Abdominal and Pararenal Abdominal Aortic Aneurysms: a Prospective, Single Centre Study of the G-Branch Endograft. Eur J Vasc Endovasc Surg. 2023. PMID: 37926150. doi:10.1016/j.ejvs.2023.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。